Clinical trials have reached inconsistent conclusions regarding the effects COX-2 inhibitors have on joint function and quality of life that is improved or unchanged following the treatment of osteoarthritis, despite pain relief being improved [39,40,41,42,43]. This evidence concerns the gene PTGS2 and osteoarthritis.